Pharvaris N.V.
PHVS- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001830487
In the last 90 days, Pharvaris N.V. insiders filed 0 open-market purchases and 18 sales; 125 institutions reported holding it in 13F filings for Q2 2026, worth $2.23B in total; Viking Global Investors is the only superinvestor holding it.
Q2 2021 vs. Q1 2021
How the institutions holding Pharvaris N.V. changed between Q1 2021 and Q2 2021.
All holders in Q2 2021All holders in Q1 2021
| Measure | Q1 2021 | Q2 2021 | Change |
|---|---|---|---|
| Holders | 33 | 28 | −5 |
| Shares | 22.0M | 22.0M | −29.3K (−0.1%) |
| Value | $616.5M | $406.3M | −$210.2M (−34.1%) |
New holders (2)
Institutions that held Pharvaris N.V. at the end of Q2 2021 but not at the end of Q1 2021.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Opaleye Management Inc. | 79,837 | $1.49M | 0.25% |
| Tower Research Capital LLC (TRC) | 561 | $11.0K | 0.00% |
Sold out (7)
Institutions that held Pharvaris N.V. at the end of Q1 2021 and filed for Q2 2021 without it.
| Institution | Shares, Q1 2021 | Value, Q1 2021 |
|---|---|---|
| Marshall Wace North America L.P. | 39,008 | $1.09M |
| Pinz Capital Management, LP | 22,650 | $634.0K |
| Zimmer Partners, LP | 15,000 | $420.0K |
| Davidson Kempner Capital Management LP | 3,500 | $98.0K |
| Rokos Capital Management LLP | 2,500 | $68.0K |
| Royal Bank of Canada | 116 | $3.00K |
| UBS Group AG | 32 | $1.00K |